A Phase II Study of Cabozantinib in Patients With <i>MET</i>-Altered Lung Cancers.

ABSTRACT:

Introduction

Only type I MET tyrosine kinase inhibitors (TKIs) are approved for treating MET-altered NSCLCs. Preclinically, type II TKIs, such as cabozantinib, can rescue progression on type I TKIs. This phase 2 trial (NCT01639508) evaluated the activity of cabozantinib in patients with MET-dependent lung cancers, including TKI-pretreated cancers.

Methods

This phase 2 trial with a Simon two-stage minimax design treated patients with metastatic, MET-altered lung cancers with cabozantinib (60 mg daily) until progression or intolerable toxicity. The primary end point was objective response rate (ORR). We prespecified that cabozantinib would be considered a useful agent if at least a 20% ORR was observed. Secondary end points included progression-free survival, ove

SUBMITTER: Harada G 

PROVIDER: S-EPMC12271782 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature